Literature DB >> 17324488

Megalin mediates the transport of leptin across the blood-CSF barrier.

Marcelo O Dietrich1, Carlos Spuch, Dessire Antequera, Izaskun Rodal, Justo G de Yébenes, José Antonio Molina, Felix Bermejo, Eva Carro.   

Abstract

Leptin, a peptide hormone secreted by adipose tissue, exhibits a large range of central and peripheral actions. It has been proposed that the participation of leptin in diseases such as obesity is due to, at least in part, its impaired transport across the blood-brain barrier (BBB). Since, the mechanisms by which brain takes up leptin remain unclear, we set out to study how leptin may cross the BBB. We have used different immunoassays and lentiviral vectors to analyze the role of megalin in the transport of leptin in rodents and humans. We demonstrate that circulating leptin is transported into the brain by binding to megalin at the choroid plexus epithelium. Indeed, the downregulation of megalin expression in physiological and pathological situations such as aging and Alzheimer's disease was correlated with poor entry of leptin into the brain. Moreover, amyloid beta (Abeta) deposits of choroid plexus could be disturbing megalin function. The present data indicate that leptin represents a novel megalin ligand of importance in the levels and therapeutic actions of leptin into the brain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324488     DOI: 10.1016/j.neurobiolaging.2007.01.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  71 in total

Review 1.  Leptin signalling pathways in hypothalamic neurons.

Authors:  Obin Kwon; Ki Woo Kim; Min-Seon Kim
Journal:  Cell Mol Life Sci       Date:  2016-01-19       Impact factor: 9.261

2.  Afamin is synthesized by cerebrovascular endothelial cells and mediates alpha-tocopherol transport across an in vitro model of the blood-brain barrier.

Authors:  Ingrid Kratzer; Eva Bernhart; Andrea Wintersperger; Astrid Hammer; Sabine Waltl; Ernst Malle; Günther Sperk; Georg Wietzorrek; Hans Dieplinger; Wolfgang Sattler
Journal:  J Neurochem       Date:  2008-11-27       Impact factor: 5.372

Review 3.  Mouse models of neurological disorders: a view from the blood-brain barrier.

Authors:  William A Banks
Journal:  Biochim Biophys Acta       Date:  2009-10-29

4.  Gut-brain communications: not the same at all ages.

Authors:  William A Banks
Journal:  Endocrinology       Date:  2010-03       Impact factor: 4.736

5.  Western style diet impairs entrance of blood-borne insulin-like growth factor-1 into the brain.

Authors:  Marcelo O Dietrich; Alexandre Muller; Marta Bolos; Eva Carro; Marcos L Perry; Luis V Portela; Diogo O Souza; Ignacio Torres-Aleman
Journal:  Neuromolecular Med       Date:  2007-09-05       Impact factor: 3.843

6.  A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Carlos Spuch; Desiree Antequera; M Isabel Fernandez-Bachiller; M Isabel Rodríguez-Franco; Eva Carro
Journal:  Neurotox Res       Date:  2009-09-23       Impact factor: 3.911

7.  Neurogenic effects of β-amyloid in the choroid plexus epithelial cells in Alzheimer's disease.

Authors:  Marta Bolos; Carlos Spuch; Lara Ordoñez-Gutierrez; Francisco Wandosell; Isidro Ferrer; Eva Carro
Journal:  Cell Mol Life Sci       Date:  2013-03-03       Impact factor: 9.261

8.  Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance.

Authors:  Joseph Tam; Resat Cinar; Jie Liu; Grzegorz Godlewski; Daniel Wesley; Tony Jourdan; Gergő Szanda; Bani Mukhopadhyay; Lee Chedester; Jeih-San Liow; Robert B Innis; Kejun Cheng; Kenner C Rice; Jeffrey R Deschamps; Robert J Chorvat; John F McElroy; George Kunos
Journal:  Cell Metab       Date:  2012-07-26       Impact factor: 27.287

9.  Gelsolin restores A beta-induced alterations in choroid plexus epithelium.

Authors:  Teo Vargas; Desiree Antequera; Cristina Ugalde; Carlos Spuch; Eva Carro
Journal:  J Biomed Biotechnol       Date:  2010-03-25

10.  Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study.

Authors:  Felix Bermejo-Pareja; Desiree Antequera; Teo Vargas; Jose A Molina; Eva Carro
Journal:  BMC Neurol       Date:  2010-11-03       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.